{"id":4529,"date":"2021-02-17T16:44:00","date_gmt":"2021-02-17T15:44:00","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=4529"},"modified":"2021-11-23T16:51:30","modified_gmt":"2021-11-23T15:51:30","slug":"association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/","title":{"rendered":"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Abstract<\/h4>\n\n\n\n<p><strong>Purpose: <\/strong>The role of angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), or other antihypertensive agents in the case of Covid-19 remains controversial. We aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19.<\/p>\n\n\n\n<p><strong>Methods<\/strong>: We performed a retrospective multicenter cohort study on patients hospitalized between February 1 and May 15, 2020. All patients had been followed up for at least 30 days.<\/p>\n\n\n\n<p><strong>Results<\/strong>: Of the 8078 hospitalized patients for Covid-19, 3686 (45.6%) had hypertension and were included in the study. In this population, the median age was 75.4 (IQR, 21.5) years and 57.1% were male. Overall in-hospital 30-day mortality was 23.1%. The main antihypertensive pharmacological classes used were calcium channel blockers (CCB) (n=1624, 44.1%), beta-blockers (n=1389, 37.7%), ARB (n=1154, 31.3%), and ACEi (n=998, 27.1%). The risk of mortality was lower in CCB (aOR, 0.83 [0.70\u20130.99]) and beta-blockers (aOR, 0.80 [0.67\u20130.95]) users and non-significant in ARB (aOR, 0.88 [0.72\u20131.06]) and ACEi (aOR, 0.83 [0.68\u20131.02]) users, compared to non-users. These results remain consistent for patients receiving CCB, beta-blocker, or<br>ARB as monotherapies.<\/p>\n\n\n\n<p><strong>Conclusion<\/strong>: This large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cardiovasc Drugs Ther. 2021 Feb 17:1\u20136. doi: 10.1007\/s10557-021-07155-5. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Mar 4;: PMID: 33595761; PMCID: PMC7887412.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-4529","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"Cardiovasc Drugs Ther. 2021 Feb 17:1\u20136. doi: 10.1007\/s10557-021-07155-5. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Mar 4;: PMID: 33595761; PMCID: PMC7887412.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-23T15:51:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/\",\"name\":\"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\"},\"datePublished\":\"2021-02-17T15:44:00+00:00\",\"dateModified\":\"2021-11-23T15:51:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.instagram.com\/fhupremimpact\/\",\"https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT","og_description":"Cardiovasc Drugs Ther. 2021 Feb 17:1\u20136. doi: 10.1007\/s10557-021-07155-5. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Mar 4;: PMID: 33595761; PMCID: PMC7887412.","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2021-11-23T15:51:30+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/","name":"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2021-02-17T15:44:00+00:00","dateModified":"2021-11-23T15:51:30+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/association-of-antihypertensive-agents-with-the-risk-of-in-hospital-death-in-patients-with-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Cardiovasc Drugs Ther. 2021 Feb 17:1\u20136. doi: 10.1007\/s10557-021-07155-5. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Mar 4;: PMID: 33595761; PMCID: PMC7887412.","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/4529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=4529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}